Why this matters Taxes shape the final price patients and consumers pay at the counter. New York’s 2024–2025 changes lowered the tax burden on medical cannabis and simplified adult-use taxes—two shifts that can influence affordability in different ways. The medical...
Why you’re hearing so much about Delta-8 Delta-8 THC (usually converted from hemp-derived CBD) remains in legal limbo. In 2025, the FDA continued issuing warning letters over safety/labeling violations, while many states moved to restrict or ban intoxicating hemp...
The headline A new peer-reviewed study following patients with primary insomnia for up to 18 months found sustained improvements in subjective sleep quality and health-related quality of life among those prescribed cannabis-based medicinal products. But it’s an...
The U.S. Department of Justice has proposed moving cannabis from Schedule I to Schedule III. If finalized, this would not legalize adult-use federally—but it would likely remove the punishing 280E tax burden going forward and could gradually lower patient costs in New...
1. Why 2025 Is a Turning Point Picture this: you walk into your primary-care clinic, discuss chronic neuropathic pain, and leave with a formal prescription for medical-grade cannabis—a prescription your insurance carrier may soon partly reimburse. That...
1. The 2.5 mg Revolution “Less is more” isn’t just a wellness meme—it’s the medical-cannabis headline of 2025. Google search interest in microdosing cannabis skyrocketed 1,250 % between 2015 and 2023 and has kept climbing as Schedule III rescheduling inches closer to...
